Draft:Golam Mohi

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Golam Mohi
Born (1969-01-01) January 1, 1969 (age 50)
NationalityBangladeshi, American
Alma mater
Known forDiscovery of the role of JAK2V617F in the pathogenesis of Myeloproliferative Neoplasms
Scientific career
FieldsBiochemistry Cell Signaling Hematology
Institutions

Golam Mohi is a professor and biochemist at the University of Virginia School of Medicine, and a National Institute of Health and Medical Research Council (United Kingdom) grant reviewer. He is accredited with being one of the leading researchers in the discovery of the role of JAK2V617F kinase in the Pathogenesis of Myeloproliferative Neoplasms[1], as well as the further discovery of the PIM1 kinase's role in hematopoietic malignancies[2]. Mohi is widely regarded as one of the leading scientists in the field of Myeloproliferative Neoplasms, and his research has been met with critical acclaim all throughout academia, having been approved for clinical trials starting in 2019. Mohi's work has also been featured multiple times in Blood (journal). Upon receiving his masters degree with honors in 1994, Mohi became the recipient of the United Kingdom Commonwealth Scholarship and Fellowship Plan, as well as the Japanese Ministry of Education, Culture, Sports, Science and Technology Monbukagakusho Scholarship. Mohi was recognized as an American Society of Hematology ASH Scholar in 2005, as well as receiving the SUNY Upstate Medical University President's Award for Excellence in Basic Research by a Young Investigator in 2012, becoming the youngest recipient of the award in institute history. He was also the recipient of the Leukemia & Lymphoma Society Scholar Award in 2013, placing him among the society’s team of highly qualified independent investigators who have made sustained original contributions in the field of leukemia. His lab is undertaking several projects, with topics including cell signaling, hematopoietic stem cell biology, molecular and epigenetic mechanisms of leukemia.[3].


References[edit]

  1. ^ http://www.bloodjournal.org/content/118/21/3861?sso-checked=true
  2. ^ Dutta A, Nath D, Yang Y, Mohi G. Abstract 1874: The PIM kinase inhibitor TP-3654 demonstrates efficacy in a murine model of myelofibrosis. Experimental and Molecular Therapeutics. 2018 https://www.cancerres.aacrjournals.org/content/78/13_Supplement/1874
  3. ^ http://bims.virginia.edu/faculty/golam-mohi/